GPIIbIIIaBlocker

GPIIbIIIa blockers are a class of antiplatelet medications that prevent blood clots from forming. They work by targeting a specific protein complex on the surface of platelets called the GPIIb/IIIa receptor. This receptor is crucial for platelet aggregation, the process by which platelets stick together to form a clot. By blocking this receptor, these drugs inhibit the final common pathway of platelet aggregation, regardless of the initial trigger.

These medications are typically administered intravenously in a hospital setting, most commonly during percutaneous coronary intervention (PCI), such as angioplasty and stenting, to prevent thrombotic complications. They are often used in conjunction with other antiplatelet agents like aspirin and a P2Y12 inhibitor. Examples of GPIIb/IIIa blockers include abciximab, eptifibatide, and tirofiban.

The primary indication for GPIIb/IIIa blockers is to reduce the risk of ischemic events in patients undergoing PCI. They are also used in some cases of acute coronary syndrome (ACS) not managed with immediate PCI, such as unstable angina or non-ST-elevation myocardial infarction, to stabilize the patient and prevent further clot formation. Due to their potent antiplatelet effect, the main side effect is bleeding, which can range from minor bruising to severe, life-threatening hemorrhage. Therefore, their use requires careful patient selection and monitoring.